X4 Pharmaceuticals (XFOR) Gross Margin (2024 - 2025)
X4 Pharmaceuticals (XFOR) posted Gross Margin of 85.83% for Q4 2025, up 7.13% on a QoQ basis from 80.11% in Q3 2025, and up 689.0% year-over-year from 10.88% in Q4 2024.
X4 Pharmaceuticals (XFOR) Gross Margin (2024 - 2025) Analysis & Trends
X4 Pharmaceuticals' Gross Margin history runs 2 years deep, the most recent figure standing at 85.83% for Q4 2025.
- Quarterly Gross Margin rose 689.0% year-over-year to 85.83% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 83.6% (up 1477.0% YoY) and the FY2025 annual result came in at 83.6%, up 1477.0% from the prior year.
- Gross Margin was 85.83% for Q4 2025 at X4 Pharmaceuticals, up from 80.11% in the prior quarter.
- Across five years, Gross Margin topped out at 85.83% in Q4 2025 and bottomed at 52.4% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 85.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 85.83% |
| Sep 30, 2025 | 80.11% |
| Jun 30, 2025 | 83.48% |
| Mar 31, 2025 | 83.63% |
| Dec 31, 2024 | 78.94% |
| Sep 30, 2024 | 59.46% |
| Jun 30, 2024 | 52.40% |